Caligan Partners
Latest statistics and disclosures from Caligan Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LQDA, RVMD, ABVX, PCVX, EXEL, and represent 69.68% of Caligan Partners's stock portfolio.
- Added to shares of these 10 stocks: RVMD (+$62M), IMCR (+$44M), VRDN (+$40M), AURA (+$29M), AVTX (+$28M), SGMT (+$19M), ARTV (+$17M), ABVX (+$13M), FTH (+$13M), IVA (+$12M).
- Started 5 new stock positions in SGMT, IMCR, ARTV, CLRB, VRDN.
- Reduced shares in these 8 stocks: MLYS (-$75M), CGON (-$61M), SYRE (-$44M), MBX (-$36M), XENE (-$30M), MAZE (-$18M), TYRA (-$15M), XLO.
- Sold out of its positions in SYRE, CGON, MAZE, MLYS, XLO.
- Caligan Partners was a net buyer of stock by $16M.
- Caligan Partners has $2.1B in assets under management (AUM), dropping by 41.45%.
- Central Index Key (CIK): 0001727492
Tip: Access up to 7 years of quarterly data
Positions held by Caligan Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Caligan Partners
Caligan Partners holds 26 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 30.5 | $647M | 8.1M | 79.73 |
|
|
| Revolution Medicines (RVMD) | 19.5 | $415M | +17% | 2.2M | 187.28 |
|
| Abivax Sa Sponsored Ads (ABVX) | 9.8 | $208M | +6% | 1.6M | 133.26 |
|
| Vaxcyte (PCVX) | 6.0 | $127M | +6% | 2.2M | 58.13 |
|
| Exelixis (EXEL) | 4.0 | $85M | 1.6M | 54.41 |
|
|
| Tango Therapeutics (TNGX) | 3.7 | $78M | +3% | 2.5M | 31.26 |
|
| Avalo Therapeutics Com New (AVTX) | 2.8 | $59M | +93% | 3.2M | 18.48 |
|
| Xenon Pharmaceuticals (XENE) | 2.5 | $54M | -36% | 890k | 60.36 |
|
| Adma Biologics (ADMA) | 2.4 | $50M | +19% | 6.0M | 8.37 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 2.2 | $47M | 1.4M | 32.45 |
|
|
| Immunocore Hldgs Ads (IMCR) | 2.1 | $44M | NEW | 1.4M | 31.75 |
|
| Miragen Therapeutics (VRDN) | 1.9 | $40M | NEW | 2.2M | 18.37 |
|
| Vor Biopharma Com New (VOR) | 1.7 | $35M | 1.9M | 18.41 |
|
|
| Sab Biotherapeutics Com New (SABS) | 1.5 | $31M | 8.0M | 3.90 |
|
|
| Inventiva Sa Ads (IVA) | 1.5 | $31M | +64% | 8.2M | 3.78 |
|
| Aura Biosciences (AURA) | 1.4 | $31M | +1769% | 4.3M | 7.10 |
|
| Tyra Biosciences (TYRA) | 1.2 | $26M | -36% | 807k | 31.94 |
|
| Ocuphire Pharma (IRD) | 1.2 | $25M | 6.1M | 4.11 |
|
|
| Anika Therapeutics (ANIK) | 1.0 | $21M | 1.4M | 14.63 |
|
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.9 | $19M | NEW | 2.5M | 7.73 |
|
| Artiva Biotherapeutics (ARTV) | 0.8 | $17M | NEW | 1.7M | 9.70 |
|
| Faeth Therapeutics Com New (FTH) | 0.7 | $16M | +399% | 630k | 25.00 |
|
| Mbx Biosciences (MBX) | 0.5 | $11M | -76% | 200k | 55.20 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.3 | $5.7M | 924k | 6.12 |
|
|
| Agios Pharmaceuticals Call Option (AGIO) | 0.2 | $3.3M | 90k | 37.11 |
|
|
| Cellectar Biosciences Com New (CLRB) | 0.1 | $1.3M | NEW | 470k | 2.78 |
|
Past Filings by Caligan Partners
SEC 13F filings are viewable for Caligan Partners going back to 2022
- Caligan Partners 2026 Q2 filed Aug. 14, 2026
- Caligan Partners 2026 Q1 filed May 15, 2026
- Caligan Partners 2025 Q4 filed Feb. 17, 2026
- Caligan Partners 2025 Q3 filed Nov. 14, 2025
- Caligan Partners 2025 Q2 filed Aug. 14, 2025
- Caligan Partners 2025 Q1 filed May 15, 2025
- Caligan Partners 2024 Q4 filed Feb. 14, 2025
- Caligan Partners 2024 Q3 filed Nov. 14, 2024
- Caligan Partners 2024 Q2 filed Aug. 14, 2024
- Caligan Partners 2024 Q1 filed May 13, 2024
- Caligan Partners 2023 Q4 filed Feb. 14, 2024
- Caligan Partners 2023 Q3 filed Nov. 14, 2023
- Caligan Partners 2023 Q2 filed Aug. 14, 2023
- Caligan Partners 2023 Q1 filed May 15, 2023
- Caligan Partners 2022 Q4 restated filed May 15, 2023
- Caligan Partners 2022 Q4 filed Feb. 15, 2023